Diana Lüftner
A5035775338- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- PARP inhibition in cancer therapy
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Radiopharmaceutical Chemistry and Applications
- Breast Lesions and Carcinomas
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Treatments and Studies
- Estrogen and related hormone effects
- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
- Pancreatic and Hepatic Oncology Research
- Management of metastatic bone disease
- Biosimilars and Bioanalytical Methods
- Neutropenia and Cancer Infections
- Ovarian cancer diagnosis and treatment
- Chemotherapy-induced cardiotoxicity and mitigation
Immanuel Krankenhaus
2022-2025
Medizinische Hochschule Brandenburg Theodor Fontane
2022-2024
Charité - Universitätsmedizin Berlin
2014-2023
CHI Health Immanuel
2022-2023
Humboldt-Universität zu Berlin
2005-2021
Freie Universität Berlin
2021
Franklin University
2013-2020
Sana Klinikum Lichtenberg
2011-2020
National Center for Tumor Diseases
2016-2019
University Hospital Heidelberg
2016-2019
To compare the effects of cannabis extract (CE), delta-9-tetrahydrocannabinol (THC), and placebo (PL) on appetite quality life (QOL) in patients with cancer-related anorexia-cachexia syndrome (CACS).Adult advanced cancer, CACS, weight loss (> or = 5% over 6 months), Eastern Cooperative Oncology Group (ECOG) performance status (PS) < 2 were randomly assigned (2:2:1) to receive CE (standardized for 2.5 mg THC 1 cannabidiol) (2.5 mg) PL orally, twice daily weeks. Appetite, mood, nausea...
438 Background: HER2 overexpression has been found in invasive UC, suggesting a role for disease progression and prognosis (Kruger Int J Oncol 2002). T-DXd is an antibody-drug conjugate comprising anti-HER2 antibody, cleavable linker, topoisomerase I inhibitor payload. Preclinical models showed that combined with anti-PD-1 antibody had greater efficacy versus either agent alone (Iwata Mol Cancer Ther 2018). We conducted phase 1b, 2-part, open-label, multicenter study of combination nivo pts...
Progress has been made in the treatment of metastatic breast cancer recent decades, but very few therapies use patient or tumor-specific characteristics to tailor individualized treatment. More than ten years after publication reference human genome sequence, analysis methods have improved enormously, fostering hope that biomarkers can be used individualize and offer precise based on tumor characteristics. Biomarkers at every level system (genetics, epigenetics, gene expression, micro-RNA,...
The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer.
Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in susceptibility genes and clinical relevance these are unclear. In this study, a prospective cohort mBC was used to determine mutation rates for (BC) predisposition genes, evaluate characteristics mutations, assess influence on patient outcome.
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
Abstract This yearʼs 18th St. Gallen (SG) consensus conference on the treatment of early breast cancer (SGBCC: International Breast Cancer Conference) focused practice-oriented questions. The individual situation and risk-benefit assessment were discussed in great detail. As previous years, a German working group leading experts presented results international SGBCC 2023 against background recommendations – especially updated Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) for...
<b><i>Introduction:</i></b> Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Cancer provides updated state-of-the-art recommendations for early metastatic breast cancer. <b><i>Methods:</i></b> The evidence-based treatment cancer have been released in March 2024. <b><i>Results Conclusion:</i></b> This...
The purpose of this retrospective study was to determine the clinical utility serum HER2/neu in monitoring metastatic breast cancer patients undergoing trastuzumab-based therapy and compare these results with those obtained using antigen (CA) 15-3. We also sought whether early changes concentrations could be a predictor progression-free survival.Sera were retrospectively from 103 women at four medical institutions. Patients eligible for participation who had tissue overexpression scheduled...
Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer. Method process updating S3 in 2012 based on adaptation identified source guidelines. They were combined with reviews evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions results a systematic search literature databases followed selection evaluation...
PurposeTreatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients advanced hormone receptor–positive, HER2-negative (HR HER2–) breast cancer (BC). However, real-world data on the implementation of usage, efficacy, toxicity have not yet been reported.MethodsThe PRAEGNANT registry was used to identify HR HER2– BC (n = 1136). The use chemotherapy, ET, everolimus CDK4/6i ET analyzed first-line, second-line, third-line therapy. Progression-free survival (PFS)...
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents 2024 update evidence-based recommendations for diagnosis and treatment patients with locally advanced metastatic breast cancer.
Abstract BACKGROUND. Previous reports based on small patient numbers suggested that changes in serum HER‐2/ neu levels may predict response or lack of to trastuzumab‐based therapies metastatic breast cancer (MBC). The objectives this study were pool data from 307 patients with MBC 7 medical institutions validate the profile predicts resistance trastuzumab and establish a clinically relevant cutoff. METHODS. This was an international, multicenter, retrospective analysis individual pooled who...
Clinical trials under-represent patients (pts) >65 years. Non-interventional studies (NISs) help to evaluate therapies in daily practice. This NIS evaluates efficacy and safety of cetuximab combination with chemotherapy metastatic colorectal cancer (mCRC) pts aged years vs ⩽65 A total 657 were recruited into the analysed applying descriptive statistics χ2 or Fisher's exact test. 309 305 years, respectively, documented; 80% showing a reduced ECOG status 1–2 95% having received at least one...